drugset / Trial / NCT02379377
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
Phase 1
Active not recruiting
110 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collab
RandomizedParallel-groupOpen-labelDiagnostic
Summary
This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant. Diagnostic procedures, such as 18F-FSPG PET, may help find and diagnose liver cancer and find out how far the disease has spread.
Timeline
- Start
- 2022-02-15
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 11C-Acetate | Diagnostic / imaging agent | — | — |
| Subject | 18F-FDG | Diagnostic / imaging agent | — | — |
| Subject | 18F-FSPG | Diagnostic / imaging agent | — | — |